^
    Back
    Association details:
    Biomarker:MGMT unmethylation
    Cancer:Glioblastoma
    Drug:lisavanbulin (BAL101553) (Apoptosis stimulant, Vascular disrupting agent, Microtubule destabilizing agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).

    Published date:
    05/25/2023
    Excerpt:
    This multicenter phase 1 study was to determine the MTD of oral Lisavanbulin in combination with standard RT (60 Gy in 30 fractions) in patients with newly diagnosed uMGMT GBM….Median OS was 12.8 months (95%CI: 9.1-18.3 months)….The median PFS was 7.7 months (95%CI: 3.0-9.5 months).
    DOI:
    10.1200/JCO.2023.41.16_suppl.2058
    Trial ID:
    NCT03250299